Premium
Etoposide with/without G‐CSF with busulfan and cyclophosphamide as conditioning for bone marrow transplantation
Author(s) -
Kanda Yoshinobu,
Akiyama Hideki,
Tanikawa Shu,
Sakamaki Hisashi,
Sasaki Tsuneo,
Takamoto Shigeru,
Onozawa Yasusuke,
Team Bmt
Publication year - 1996
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/(sici)1096-8652(199604)51:4<265::aid-ajh3>3.0.co;2-u
Subject(s) - busulfan , medicine , etoposide , cyclophosphamide , mucositis , gastroenterology , toxicity , transplantation , bone marrow , regimen , chemotherapy , surgery
To increase the efficacy of bone marrow transplantation (BMT), we have tried to add etoposide (VP‐16) to busulfan/cyclophosphamide (BU/CY). Twelve patients received 16 mg/kg of BU and 120 mg/kg of CY with 15–30 mg/kg of VP‐16. Another two patients received 5 μg/kg of G‐CSF with 30 mg/kg of VP‐16. Patients tolerated escalating doses of VP‐16 without any significant hepatotoxicity. Their maximal level of bilirubin was 37.6 μmol/L (2.2 mg/dl), and there was no significant skin toxicity or mucositis. By contrast, two patients who received G‐CSF with 30 mg/kg of VP‐16 developed hyperbilirubinemia and veno‐occlusive disease, which terminated this phase I study. VP‐16 can be safely combined with BU/CY ≤30 mg/kg in three divided doses, and its effect on survival should be evaluated. G‐CSF added to this regimen, however, should be used with great caution. © 1996 Wiley‐Liss, Inc.